• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
Conclusions In this small, open-label, randomised trial of non-critically ill hospitalised patients with COVID-19, the combination of colchicine and rosuvastatin in addition to standard of care did not appear to reduce the risk of progression of COVID-19 disease or thromboembolic events, although the trial was underpowered due to a lower-than-expected event rate. The trial leveraged the power of electronic medical records for efficiency and improved follow-up and demonstrates the utility of incorporating electronic medical records into future trials. Trial registration NCT04472611.
Source: BMJ Open - February 24, 2023 Category: General Medicine Authors: Shah, T., McCarthy, M., Nasir, I., Archer, H., Ragheb, E., Kluger, J., Kashyap, N., Paredes, C., Patel, P., Lu, J., Kandel, P., Song, C., Khan, M., Huang, H., Ul Haq, F., Ahmad, R., Howes, C., Cambi, B., Lancaster, G., Cleman, M., Dela Cruz, C., Parise, H Tags: Open access, Infectious diseases, COVID-19 Source Type: research

Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials
Introduction Inflammation is emerging as an important risk factor for atherosclerotic cardiovascular disease and has been a recent target for many novel therapeutic agents. However, comparative evidence regarding efficacy of these anti-inflammatory treatment options is currently lacking. Methods and analysis This systematic review will include randomised controlled trials evaluating the effect of anti-inflammatory agents on cardiovascular outcomes in patients with known cardiovascular disease. Studies will be retrieved from Medline, Embase, the Cochrane Central Register of Controlled Trials, as well as clinical trial regi...
Source: BMJ Open - June 27, 2022 Category: General Medicine Authors: Boczar, K. E., Shin, S., Bezzina, K. A., Geejo, A., Pearson, A. L., Shahab, S., Fehlmann, C. A., Visintini, S., Beanlands, R., Wells, G. A. Tags: Open access, Cardiovascular medicine Source Type: research

Gout Medicine Colchicine May Also Help Fight Heart Failure
MONDAY, May 23, 2022 -- The anti-inflammatory benefits of a common gout medicine may help save the lives of heart failure patients, researchers say. The medication, colchicine, could also reduce the risk of heart attack and stroke in patients whose...
Source: Drugs.com - Daily MedNews - May 23, 2022 Category: General Medicine Source Type: news

Colchicine for prevention of cardiovascular events.
CONCLUSIONS: There is much uncertainty surrounding the benefits and harms of colchicine treatment. Colchicine may have substantial benefits in reducing myocardial infarction in selected high-risk populations but uncertainty about the size of the effect on survival and other cardiovascular outcomes is high, especially in the general population from which most of the studies in our review were drawn. Colchicine is associated with gastrointestinal side effects based on low-quality evidence. More evidence from large-scale randomised trials is needed. PMID: 26816301 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - January 27, 2016 Category: Journals (General) Authors: Hemkens LG, Ewald H, Gloy VL, Arpagaus A, Olu KK, Nidorf M, Glinz D, Nordmann AJ, Briel M Tags: Cochrane Database Syst Rev Source Type: research